Bupropion (Wellbutrin) for ADHD in adults

Bupropion (Wellbutrin and generics) is an antidepressant that some prescribers use for adult ADHD. It is not FDA-approved for ADHD, so that use is off-label. The research behind it is real but small and of low quality. This page sets out what the FDA labels say, what the evidence shows for adults with ADHD, and the safety points that matter, with labels checked on October 19, 2026. It is not advice to start, stop or switch any medication.

What bupropion is approved for

Bupropion is described on its labels as an aminoketone antidepressant. The approved uses depend on the product:

• Wellbutrin XL (extended-release tablets): major depressive disorder, and prevention of seasonal major depressive episodes in seasonal affective disorder.
• Wellbutrin SR (sustained-release tablets): major depressive disorder.
• Bupropion SR for smoking cessation: indicated "as an aid to smoking cessation treatment."

ADHD is not on any of these labels. The Cochrane review of bupropion for adult ADHD describes it as "registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD," and a 2024 review in American Family Physician notes that bupropion "is not approved by the U.S. Food and Drug Administration for ADHD."

The FDA explains that once a drug is approved, healthcare providers generally may prescribe it for an unapproved use when they judge it medically appropriate, but that the FDA has not determined it is safe and effective for that use. Asking what evidence supports it for you is reasonable.

Why it is considered for ADHD

Bupropion affects the same brain messengers that ADHD medicines target. The Cochrane review describes it as an aminoketone antidepressant that also blocks nicotinic acetylcholine receptors, and its label notes that animal studies show some pharmacologic actions common to stimulants. It is not a controlled substance; the label says so directly.

Practical reasons a prescriber might raise it: a stimulant was not tolerated or is not suitable, a non-controlled option is preferred, or depression or smoking is present alongside ADHD. The American Family Physician review lists atomoxetine, viloxazine and bupropion as options "for adults unable to take stimulants or with concurrent anxiety/depression." How ADHD and depression interact is covered in ADHD and depression in adults.

What the evidence shows

The Cochrane authors concluded that the findings "indicate a possible benefit," that extended- or sustained-release bupropion "may be an alternative to stimulants," and that further research "is very likely to change these estimates." All six trials used long-acting forms. Four excluded people with other psychiatric conditions, which limits how well the results apply to adults who have both ADHD and depression.

The UK's NICE guideline does not include bupropion among its recommended adult ADHD medications, and it says medicines outside its list should not be offered for ADHD without advice from a tertiary ADHD service. The broader picture of how first-line choices are made is in how doctors choose an ADHD medication and other off-label ADHD medications.

Forms and generics

The labels refer to immediate-release, sustained-release (SR) and extended-release (XL) formulations, and generic versions are sold. The ADHD trials in the Cochrane review all used long-acting versions. Because the products differ in release pattern and approved uses, confirm with the pharmacist which one you have been given.

Boxed warning

Like all antidepressants, bupropion carries a boxed warning: antidepressants "increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials." The label says patients of all ages starting an antidepressant should be monitored for worsening and for suicidal thoughts. Young adults are included in that warning. In a crisis, call or text 988.

Who should not take it

The Wellbutrin XL label lists these contraindications:

• A seizure disorder
• A current or past diagnosis of bulimia or anorexia nervosa, because of a higher seizure rate
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs
• Use with an MAOI for psychiatric conditions, or within 14 days of one; starting it in someone receiving linezolid or intravenous methylene blue
• Known allergy to bupropion

Other warnings

• Seizures. The risk is dose-related. This is the reason the label sets dose limits and lists eating disorders and alcohol or sedative withdrawal as contraindications.
• Blood pressure. Bupropion can raise blood pressure; the label asks for checks before and during treatment.
• Mania. Patients should be screened for bipolar disorder.
• Psychosis and other neuropsychiatric reactions, and neuropsychiatric events reported during smoking cessation.
• Angle-closure glaucoma in people with untreated narrow angles.

Common side effects

The Wellbutrin XL label lists, among the most common reactions, dry mouth, nausea, insomnia, dizziness, sore throat, abdominal pain, agitation, anxiety, tremor, palpitations, sweating, ringing in the ears, muscle aches, loss of appetite, urinary frequency and rash.

Interactions worth knowing

• CYP2D6. Bupropion inhibits this enzyme and can raise levels of some antidepressants, antipsychotics, beta-blockers such as metoprolol, and certain heart rhythm drugs.
• Drugs that lower the seizure threshold call for caution.
• Levodopa and amantadine can cause central nervous system toxicity with bupropion.
• Drug tests. The label says bupropion can cause false-positive urine tests for amphetamines. If you are tested at work, see ADHD medication and workplace drug tests.

More in ADHD medication drug interactions.

Pregnancy and breastfeeding

The label reports that bupropion and its metabolites are present in human milk and that limited postmarketing reports have not identified a clear association with adverse reactions in breastfed infants. NIH LactMed has a detailed entry.

New York and New Jersey rules

Because bupropion is not a controlled substance, the Schedule II rules that apply to ADHD stimulants (New York's 10 NYCRR 80.67, New Jersey's in-person requirements for Schedule II stimulants started by telehealth under P.L.2026, c.40, and DEA telemedicine rules) do not apply. For stimulant rules, see New York and New Jersey.

Questions to ask your prescriber

• Why bupropion instead of an FDA-approved ADHD medication for me?
• Is it meant to treat ADHD, depression, or both?
• Does my history include anything that raises seizure risk?
• How will we judge whether ADHD symptoms are improving?

Dr. Shershow evaluates adults for ADHD, including whether depression or anxiety is part of the picture, and discusses medication options and their label status as part of a treatment plan. See adult ADHD evaluation.